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• Identify high-impact specialty pipeline drugs 
expected to reach the market in 2017-2018 
• Summarize efficacy data for high-impact specialty 
pipeline drugs and indicate their anticipated place 
in therapy 
• Compare specialty pipeline drugs to currently 
available therapeutic options 
• Predict the budgetary impact of specialty pipeline 
drugs and discuss strategies to mitigate costs 
Objectives 
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Two key drivers 
• Clinical impact 
– Efficacy/effectiveness 
– Therapeutic alternatives 
• Economic impact 
– Cost 
– Volume 
Identifying High-Impact Drugs 
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Assessing Clinical Impact 
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Clinical trial data 
• Placebo-controlled, 
head-to-head studies 
• Adverse events 
• Potential drug-drug 
interactions 
• Target population 
• Patient willingness to 
use medication 
Therapeutic alternatives 
• Me-too drug vs. first-in-class 
• Market competition 
• Consensus guidelines 
Assessing Economic Impact 
AHRQ=Agency for Healthcare Research and Quality, AWP=average wholesale price, 
ICER=Institute for Clinical and Economic Review, PCORI=Patient-centered Outcomes 
Research Institute, WAC=wholesale acquisition cost 
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Cost 
• AWP/WAC 
• Supplemental rebate 
• Value-based contracts 
• Value assessments  
(e.g., AHRQ, ICER, PCORI) 
Volume 
• Prevalence/incidence of 
disease 
• Frequency of administration 
• Duration of therapy 
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• Proactive pharmaceutical pipeline monitoring 
– Focus on high-cost disease states, specialty drugs (e.g., 
NASH, hepatitis C, PCSK9 inhibitors, oncology, monoclonal 
antibodies) 
• Budget impact analysis completed for drugs with 
potentially high clinical and economic impact 
– Medical claims data to determine prevalence 
– Estimate market share/uptake 
– Cost 
Assessing Budget Impact 
NASH=non-alcoholic steatohepatitis, PCSK9=proprotein convertase subtilisin/kexin type 9 
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• Uptake may not be as quick as anticipated 
– Skepticism surrounding safety of new treatments 
– Consensus guideline updates take time 
– Clinical inertia 
– Patient willingness to try new medications 
• Recent examples 
– PCSK9 inhibitors – uptake remains low and slow 
– HCV – 5.1% of MA Medicaid members with HCV had 
PA requests for sofosbuvir or simeprevir in first 1.5 
years on market 
Lessons Learned1 
HCV=hepatitis C virus, PA=prior authorization 
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HIGH-IMPACT PIPELINE DRUGS 
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Sub-group of non-alcoholic fatty liver disease (NAFLD) 
• Significant morbidity and mortality 
– 11% of patients progress to cirrhosis 
– 7% of patients develop hepatocellular carcinoma 
– 10-fold increased risk of liver-related death 
– Two-fold increased CV risk 
• CV events are the leading cause of death 
• Second most common cause of liver disease in adults 
awaiting liver transplant in US 
Non-alcoholic Steatohepatitis (NASH)2-6 
CV=cardiovascular 
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• Closely associated with obesity, T2DM, dyslipidemia 
• Histologic features: hepatic steatosis, hepatic cell injury, 
inflammation, fibrosis 
• Presence and degree of NASH measured by NAFLD 
activity score (NAS) 
– Steatosis (0 to 3) 
– Lobular inflammation (0 to 3) 
– Hepatocellular ballooning (0 to 2) 
Non-alcoholic Steatohepatitis (NASH)2-6 
T2DM=type 2 diabetes mellitus 
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• Proposed indication: NASH 
• MOA: Dual PPAR-α/δ agonist 
– PPARs play a key role in metabolic homeostasis, 
immune-inflammation, and differentiation 
– May improve histology in NASH, reduce TG, increase 
HDL, improve glucose homeostasis 
– Reduced markers of liver inflammation in Phase IIa trials 
 
Elafiabranor2-3 
HDL=high-density lipoprotein, MOA=mechanism of action, PPAR=peroxisome proliferator-activated 
receptor, TG=triglycerides 
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Phase II GOLDEN-505 trial: Design 
• Randomized, placebo-controlled 
• Population: N=274; histologic diagnosis of  
non-cirrhotic NASH 
• Intervention: elafibranor 80 mg or 120 mg by 
mouth once daily or placebo for 52 weeks 
• Primary outcome: reversal of NASH without 
worsening of fibrosis 
– Absence of ≥1 of 3 components of NASH  
(i.e., steatosis, ballooning, inflammation) 
 
Elafibranor: Clinical Impact2 
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Phase II GOLDEN-505 trial: Results 
• Resolution of NASH without worsening fibrosis: 
Protocol-defined definition 
– No difference in response rate overall 
• 23%, 21%, and 17% for elafibranor 80 mg, 120 mg, 
and placebo, respectively; P=0.280 
– Post-hoc analysis of patients with NAS ≥4: significant 
difference in response rate 
• 20%, 20%, and 11% for elafibranor 80 mg, 120 mg, 
and placebo, respectively; P=0.018 
 
Elafibranor: Clinical Impact2 
NAS=NAFLD activity score 
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Phase II GOLDEN-505 trial: Results 
• Resolution of NASH without worsening fibrosis: 
Modified* definition 
– Significant improvement in response rate with 
elafibranor 120 mg vs. placebo 
• All patients:19% vs. 12% for elafibranor 120 mg 
and placebo, respectively (P=0.045) 
• Baseline NAS ≥4: 19% vs. 9% for elafibranor 
120 mg and placebo, respectively (P=0.013) 
 
Elafibranor: Clinical Impact2 
*Modified definition of resolution of NASH: disappearance of ballooning together with either disappearance 
of lobular inflammation or persistence of mild lobular inflammation 
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Phase II GOLDEN-505 trial: Results 
• Patients with NASH resolution on elafibranor 120 mg 
– Improvement in liver fibrosis: -0.65±0.61 in responders 
vs. 0.10±0.98 in non-responders (P<0.001) 
– Significant improvements in steatosis, ballooning, and 
inflammation vs. non-responders (P<0.05, P<0.001, 
and P<0.05, respectively) 
 
Elafibranor: Clinical Impact2 
November 16, 2016 Planning for the 2017 Specialty Drug Spend 16 
 |
  
 
|
  
Therapeutic alternatives 
• No FDA-approved treatments indicated for NASH 
• Weight loss  
• Treatment of risk factors for CVD 
– Diabetes, dyslipidemia 
• Vitamin E is first-line pharmacotherapy* 
– Improves liver histology 
• Pioglitazone may be used  
– Lack of long-term safety/efficacy data, potential AEs 
 
Elafibranor: Clinical Impact4 
*In the absence of diabetes 
AE=adverse events, CVD=cardiovascular disease 
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NASH Pipeline* 
• Obetacholic acid (OCA) 
– FXR ligand FDA-approved for primary biliary cholangitis 
(PBC) 
– ICER evidence rating of “insufficient” based on clinical 
trial data and unanswered questions 
• Phase IIb FLINT study achieved primary endpoint 
• Unpublished Phase II study in Japanese patients 
missed primary endpoint 
 
Elafibranor: Clinical Impact2,5-6 
*Not an all-inclusive list 
FXR=farnesoid X nuclear receptor 
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Cost 
• Cost data not available for elafibranor 
• OCA recently approved for PBC 
– ~$18,000/month* for off-label treatment of NASH 
• Supplemental rebate – preferred NASH product 
• Value-based contracts – low response rates 
 
Elafibranor: Economic Impact6-9 
*WAC 
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Volume 
• Prevalence 3.5% to 5% with ~5% diagnosed 
– ICER estimates 567,000 individuals eligible for treatment  
– ICER estimates low uptake of ~10% 
• Duration of treatment indefinite 
– Treatment continues until progression to cirrhosis (liver 
transplant) or until resolution (F0) 
 
Elafibranor: Economic Impact6 
F0=fibrosis stage 0 
November 16, 2016 Planning for the 2017 Specialty Drug Spend 20 
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• Medicaid plan 
– $72,000/year for treatment 
– Scenarios 
• 10% uptake: $1.3 to  
$1.8 million per year 
• All diagnosed patients  
treated: $12.6 to  
$18 million per year 
• Timeline 
– Awarded Fast Track designation 
– Approval anticipated ~2018-2019 
 
Elafibranor: Budget Impact6-9 
100,000  
covered lives 
3,500-5,000  
patients with NASH 
175-250  
patients  
diagnosed/ 
may require 
treatment 
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Atopic Dermatitis10-12 
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Clinical features 
• Chronic, inflammatory 
skin condition 
• Characterized by rash, 
scaly patches on skin, 
intense itching 
• May lead to skin 
infection 
Prevalence  
• Affects 7% to 30% of 
children and 1% to 10% of 
adults with 95% of cases 
starting before age 5 
• 50% of patients with atopic 
dermatitis in childhood 
continue to have milder 
symptoms as an adult 
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• Proposed indication: atopic dermatitis 
• MOA: MoAB targeting IL-4/IL-13 
– IL-4/IL-13 signaling pathway implicated in  
inflammatory response 
– SC injection 
• If approved, dupilumab would be the first biologic 
indicated for atopic dermatitis 
 
Dupilumab10-12 
IL=interleukin, MoAB=monoclonal antibody, SC=subcutaneous 
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Phase III LIBERTY AD CHRONOS trial: Design 
• Randomized, placebo-controlled 
• Population: N=740; adults with moderate-to-severe 
atopic dermatitis 
• Intervention: dupilumab 300 mg SC QW, 300 mg  
SC Q2W, or placebo 
– All patients received medium potency TCS* 
• Primary outcome: proportion of patients achieving  
IGA 0 or 1 at 16 weeks 
 
Dupilumab: Clinical Impact13 
* Low potency TCS used for areas where medium potency TCS were deemed unsafe 
IGA=Investigator’s Global Assessment Scale, QW=once weekly, Q2W=every two weeks, TCS=topical 
corticosteroids 
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Phase III LIBERTY AD CHRONOS trial: Results 
 
Dupilumab: Clinical Impact13 
EASI-75=75% reduction in Eczema Activity and Severity Index score, QW=once weekly, Q2W=every two 
weeks 
Outcome 
Dupilumab  
300 mg QW 
Dupilumab  
300 mg Q2W 
Placebo 
Primary endpoints 
Proportion of patients 
with IGA 0 or 1 at 16 
weeks 
39% 
(P<0.0001) 
39% 
(P<0.0001) 
12% 
Proportion of patients 
with EASI-75 at 16 
weeks 
64% 
(P<0.0001) 
69% 
(P<0.0001) 
23% 
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Phase III LIBERTY AD CHRONOS trial: Results 
 
Dupilumab: Clinical Impact13 
Outcome 
Dupilumab  
300 mg QW 
Dupilumab  
300 mg Q2W 
Placebo 
Secondary endpoints 
Proportion of patients 
with IGA 0 or 1 at 52 
weeks 
40% 
(P<0.0001) 
36% 
(P<0.0001) 
12.5% 
Proportion of patients 
with EASI-75 at 52 
weeks 
64% 
(P<0.0001) 
65% 
(P<0.0001) 
22% 
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Therapeutic alternatives 
• TCS, emollients 
• Topical calcineurin inhibitors  
– e.g., tacrolimus, pimecrolimus 
• Phototherapy 
• Systemic immunosuppressant therapy 
– e.g., cyclosporine 
• First generation antihistamines may help improve sleep 
 
Dupilumab: Clinical Impact14-15 
November 16, 2016 Planning for the 2017 Specialty Drug Spend 27 
Dupilumab: Clinical Impact11,13-15 
SOC=standard of care 
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Potential Advantages 
• Significant improvements 
in outcomes vs. SOC 
• Potential for Q2W dosing 
• May be the first targeted 
therapy for underlying 
cause of disease 
• Well-tolerated safety 
profile 
Potential Disdvantages 
• Current SOC is much less 
costly 
• SC administration for a 
disease historically treated 
topically 
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Cost 
• Cost data not available  
• Industry news blasts suggest $30,000/year 
• Supplemental rebate – limited market competition 
• Value-based contracts – some subjectivity in 
treatment outcomes, monitoring issues 
 
Dupilumab: Economic Impact16 
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Volume 
• Prevalence 10.7% of children, 10.2% of adults 
– Estimated that 33% of children with atopic dermatitis 
have moderate-to-severe disease 
– 7 to 8 million adults in the US; approximately 1.6 million 
with uncontrolled disease per physician survey 
• Duration of treatment is indefinite 
• Other key facts 
– Also being studied in asthma, nasal polyposis 
 
Dupilumab: Economic Impact17-20 
November 16, 2016 Planning for the 2017 Specialty Drug Spend 30 
 |
  
 
|
  
Medicaid plan 
• Up to $30,000/year  
for treatment 
• Scenarios 
– 10% uptake: $2 to  
$2.5 million/year 
– All uncontrolled  
patients treated:  
$19.8 to  
$24.8 million/year 
 
Dupilumab: Budget Impact13,16,21 
100,000  
covered lives 
10,000  
patients with  
atopic dermatitis 
3,300  
patients with  
moderate-to-severe  
disease 
660 to 825  
patients may be 
uncontrolled and  
require treatment 
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Timeline 
• Awarded Breakthrough Therapy designation 
• Regulatory submission completed Q3 2016 
• FDA decision may be expected in the first half of 2017 
 
Dupilumab: Budget Impact13 
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Multiple Sclerosis22-25 
MS=multiple sclerosis, PPMS=primary-progressive MS, PRMS=progressive-relapsing MS, 
RRMS=relapsing-remitting MS, SPMS=secondary-progressive MS 
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Clinical features 
• Chronic, immune-mediated disease 
• Immune system attacks myelin, nerve 
fibers 
• Characterized by sensory 
disturbances; numbness/weakness, 
vision loss, pain, tremor, fatigue, etc. 
• Four subtypes: RRMS, PPMS, SPMS, 
PRMS 
Prevalence 
• Affects 400,000 
people in the US 
• More common  
in women than 
men 
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• Proposed indication: Relapsing MS, PPMS 
• MOA: MoAB that selectively targets CD20-positive 
B cells 
– CD20-positive B cells are key contributors to myelin and 
axonal damage 
– Ocrelizumab binds to CD20 cell surface proteins 
expressed on B cells (not stem or plasma cells), 
preserving key functions of the immune system 
 
Ocrelizumab26 
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Phase III OPERA I and II trials: Design 
• Randomized, active-controlled 
• Population: N=828; patients with RRMS 
• Intervention: ocrelizumab 600 mg IV infusion every 
six months or interferon β-1a 44 mcg SC thrice 
weekly for two years 
• Primary outcomes: ARR at 96 weeks 
 
Ocrelizumab: Clinical Impact27 
ARR=annualized relapse rate, IV=intravenous 
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Phase III OPERA I and II trials: Results 
 
Ocrelizumab: Clinical Impact27 
Outcome IFN β-1a Ocrelizumab 
Relative 
reduction  
ARR at 96 weeks 
OPERA I 0.292 0.156 
46%  
(P<0.0001) 
OPERA II 0.290 0.155 
47% 
(P<0.0001) 
IFN=interferon 
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Phase III OPERA I and II trials: Results 
 
Ocrelizumab: Clinical Impact27 
Outcome Ocrelizumab IFN β-1a 
Relative 
reduction  
T1 GdE lesions 
OPERA I 0.016 0.286 
94% 
(P<0.0001) 
OPERA II 0.021 0.416 
95% 
(P<0.0001) 
GdE=gadolinium-enhancing lesions 
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Phase III ORATORIO trial: Design 
• Randomized, placebo-controlled 
• Population: N=732; patients with PPMS 
• Intervention: ocrelizumab 600 mg IV infusion every six 
months or placebo (minimum of 5 doses) 
– All patients pre-medicated with methylprednisolone 
• Primary outcomes: progression of clinical disability  
 
Ocrelizumab: Clinical Impact26-27 
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Phase III ORATORIO trial: Results 
 
Ocrelizumab: Clinical Impact26-27 
EDSS=Expanded Disability Status Scale 
Outcome 
Risk reduction 
(ocrelizumab vs. placebo) 
P-value 
Primary Endpoint 
Risk of progression of clinical 
disability sustained for ≥12 
weeks (per EDSS) 
24% 0.0321 
Secondary Endpoint 
Risk of progression of clinical 
disability sustained for ≥24 
weeks (per EDSS) 
25% 0.0365 
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Phase III ORATORIO trial: Results 
 
Ocrelizumab: Clinical Impact26-27 
Outcome Ocrelizumab Placebo P-value 
Secondary Endpoints at 120 weeks 
Change from baseline in 
time to walk 25 feet 
39% 55% 0.04 
Change from baseline in 
T2 lesion volume 
-3.4% 7.4% <0.0001 
Rate of brain volume loss 
(from baseline) 
-0.9% -1.1% 0.02 
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Ocrelizumab: Clinical Impact28-31 
Therapeutic alternatives 
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Injectable 
• IFN β-1a 
• IFN β-1b 
• Daclizumab 
• Glatiramer acetate 
• Natalizumab 
• Alemtuzumab 
• Mitoxantrone 
Oral 
• Fingolimod 
• Teriflunomide 
• Dimethyl fumarate 
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MS Pipeline 
• Ozanimod 
– Oral, S1P receptor 1 and 5 modulator 
• Selectivity may avoid AEs associated with fingolimod 
– RRMS: ↓MRI brain lesions by 86% and ↓ARR* by 53% 
vs. placebo 
– Regulatory submission for MS anticipated 2017-2018 
 
Ocrelizumab: Clinical Impact22-25 
*Not statistically powered to detect significance  
S1P=sphingosine 1-phosphate 
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MS Pipeline* 
 
Ocrelizumab: Clinical Impact32 
*Not an all-inclusive list 
Generic  
Name 
MOA 
Proposed 
Indication(s) 
Anticipated 
Approval 
Laquinimod 
Immuno-
modulator 
RRMS 2017 
Siponimod 
S1P receptor 1 
and 5 inhibitor 
RRMS,  
PPMS, SPMS 
2017 
Ponesimod 
S1P receptor 1 
inhibitor 
RRMS 2018 
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Ocrelizumab: Clinical Impact27,33-36 
LE=lupus erythematosus, RA=rheumatoid arthritis  
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Potential Advantages 
• May be the first  
FDA-approved  
treatment for PPMS 
• Significantly reduced risk 
of disease progression in 
difficult-to-treat PPMS  
• Dosed every six months 
vs. every month with 
natalizumab 
Potential Disadvantages 
• Higher doses in Phase III  
RA trial were associated  
with serious, opportunistic 
infections 
• Development in RA, LE  
halted due to incidence of 
opportunistic infection and 
death in clinical trials 
• Lacking long-term safety data 
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Cost 
• Cost data not available 
– Currently available injectable agents range in cost from 
$1,000 to $106,000 per year (most ~$80,000) 
• Supplemental rebate – limited market competition for 
PPMS; may select preferred RRMS agent 
• Value-based contracts – reduction in risk of 
progression (PPMS), reduction in ARR (RRMS) 
Ocrelizumab: Economic Impact32,36 
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Volume 
• Prevalence 90 per 100,000 individuals in US 
• Duration: chronic condition; treatment is indefinite 
• Other key facts 
– May be the first approved treatment for PPMS 
– Several injectable, oral options on the market for RRMS 
– Injectable agents ~70% of the RRMS market 
Ocrelizumab: Economic Impact22,29,32-34 
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• Medicaid plan  
– Approximately  
$80,000/year  
for treatment 
– $4.8 million/year 
• Timeline 
– FDA decision 
expected 12/28/2016 
Ocrelizumab: Budget Impact37 
100,000  
covered lives 
90 
patients with MS 
60 
patients  
may require 
treatment 
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Plaque Psoriasis38,39 
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Clinical features 
• Chronic, immune-mediated 
disease 
• Characterized by infiltration of 
inflammatory cells into the 
skin, excessive keratinocyte 
proliferation, and development 
of raised, scaly skin (plaques) 
• ↑ incidence of lymphoma, heart 
disease, obesity, T2DM, 
metabolic syndrome 
Prevalence 
• Affects ~6 million people 
in the US 
• Most common form of 
psoriasis 
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• Proposed indication: plaque psoriasis 
• MOA: fully-human MoAB that inhibits IL-23 
– Specifically targets the p19 subunit of IL-23  
(p19 mRNA elevated in psoriatic lesions) 
– Th17/IL-23 pathway key in amplification phase 
of psoriasis 
– SC injection 
 
Guselkumab40 
mRNA=messenger ribonucleic acid, Th=T helper cell 
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Phase III VOYAGE 1 trial: Design 
• Randomized, placebo- and active-controlled 
• Population: N=837; adults with moderate-to-severe plaque psoriasis 
• Intervention:  
– Placebo at weeks 0, 4, 12 then guselkumab at weeks 16 and 20 and 
Q8W thereafter 
– Guselkumab 100 mg SC at weeks 0, 4, 12 then Q8W 
– Adalimumab 80 mg SC at week 0, 40 mg at week 1, then Q2W 
thereafter 
• Primary outcomes: PASI90 response, IGA of 0 or 1 at 16 weeks vs. 
placebo 
 
Guselkumab: Clinical Impact41,42 
IGA=Investigator’s Global Assessment, PASI90=90% improvement in Psoriasis Area Sensitivity Index, 
Q2W=every two weeks, Q8W=every eight weeks 
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Phase III VOYAGE 1 trial: Results 
 
Guselkumab: Clinical Impact41,42 
Outcome Guselkumab Placebo P-value 
Primary Endpoints vs. Placebo 
Proportion of patients 
achieving PASI90 at 16 
weeks 
73.3% 2.9% <0.001 
Proportion of patients 
achieving IGA 0 or 1 at 16 
weeks 
85.1% 6.9% <0.001 
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Phase III VOYAGE 1 trial: Results 
 
Guselkumab: Clinical Impact41,42 
Outcome Guselkumab Adalimumab P-value 
Primary Endpoints vs. Adalimumab 
Proportion of patients 
achieving PASI90 at 16 
weeks 
73.3% 49.7% <0.001 
Proportion of patients 
achieving IGA 0 or 1 at 
16 weeks 
85.1% 65.9% <0.001 
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Therapeutic alternatives 
• Topical 
– Emollients, keratolytics, corticosteroids, etc. 
• Systemic 
– Traditional DMARDs 
• MTX, sulfasalazine, cyclosporine, tacrolimus, azathioprine, 
hydroxyurea, leflunomide, etc. 
– Biologic DMARDs  
• Adalimumab*, etanercept*, infliximab, ixekizumab, 
secukinumab, ustekinumab* 
• Phototherapy 
 
Guselkumab: Clinical Impact43-47 
*Recommended as first-line treatment option per consensus guidelines 
DMARD=disease-modifying antirheumatic drug, MTX=methotrexate 
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Plaque Psoriasis Pipeline* 
• Brodalumab 
– Investigational fully-human IL-17 receptor MoAB 
– SC injection 
– FDA AdComm voted 18-0 in favor of approval with 
conditions related to product labeling, post-
marketing/risk management requirements 
• Safety concerns: increased risk of suicidal ideation 
and behavior, serious infections 
– FDA decision expected 11/16/2016  
Guselkumab: Clinical Impact48 
*Not an all-inclusive list 
AdComm=Advisory Committee 
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Plaque Psoriasis Pipeline* 
• Tildrakizumab 
– Investigational fully-human IL-23 receptor antibody 
targeting p19 subunit 
– SC injection 
– Demonstrated superiority vs. placebo and etanercept in 
Phase III trials† 
• PASI75 response at week 12 
• PGA response (score of 0 or 1 with ≥2 point reduction) 
– BLA anticipated late 2016 
Guselkumab: Clinical Impact49 
*Not an all-inclusive list 
†Tildrakizumab 100 mg was superior to etanercept for PASI75, only 
PASI75=75% improvement in Psoriasis Area Sensitivity Index 
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Guselkumab: Clinical Impact27,33-36 
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Potential Advantages 
• Demonstrated superior 
efficacy vs. adalimumab, 
current market leader 
• Similar safety profile 
compared to adalimumab 
in clinical trials 
• Ongoing clinical trial 
comparing guselkumab to 
ustekinumab 
Potential Disadvantages 
• Biosimilars for market 
leaders, including 
adalimumab 
• Crowded plaque psoriasis 
market 
• Brodalumab may reach 
market first 
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Cost 
• Cost data not available 
– Adalimumab, etanercept, and ustekinumab cost  
~$37,000 to $57,000 per year 
• Supplemental rebate – identify preferred IL-23 agent 
– Crowded plaque psoriasis market, biosimilars 
• Value-based contracts – achievement of PASI 75, PGA 
response 
Guselkumab: Economic Impact40,43-47 
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Volume 
• Prevalence: 2% of the US population has psoriasis; 
90% of patients with psoriasis have plaque psoriasis 
– Approximately 20% have moderate-to-severe disease 
• Duration: chronic condition; duration of treatment is 
indefinite 
• Other key facts 
– Given superior efficacy vs. adalimumab, may become 
a first-line treatment option 
– Also being studied in psoriatic arthritis 
 
Guselkumab: Economic Impact38,39 
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Medicaid plan 
• Approximately 
$50,000/year for 
treatment 
• $6 million/year 
Timeline 
• Regulatory submission 
anticipated Q4 2016 
Guselkumab: Budget Impact38,40,43-47 
100,000  
covered lives 
1,800  
patients with  
plaque psoriasis 
360  
patients with  
moderate-to-severe 
 disease 
120 
patients may  
require treatment 
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Migraine50-52 
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Clinical features 
• May be episodic (0 to 14 
headache days/month) or 
chronic (≥15 headache 
days/month)  
• Characterized by incapacitating 
head pain, physical impairment; 
commonly associated with 
nausea, vomiting, and  
sound/sensory disturbances 
Prevalence 
• Affects ~3 to 7 million 
people in the US 
• Health care and lost 
productivity costs 
associated with migraine 
~$36 billion/year in  
the US 
 |
  
 
|
  
• Proposed indication: prevention of episodic 
migraine, chronic migraine 
• MOA: fully-human MoAB targeting CGRP receptor 
– CGRP receptors are thought to transmit signals that can 
cause incapacitating pain  
– Blocking CGRP reduces vasodilation and neurogenic 
inflammation associated with migraine 
Erenumab53-55 
CGRP=calcitonin-gene related peptide 
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Phase III ARISE trial: Design 
• Randomized, placebo-controlled 
• Population: N=577; patients with episodic migraine 
– Average of 8 migraines/month at baseline 
• Intervention: erenumab 70 mg SC monthly vs. placebo 
• Primary outcome: change in monthly migraine days from 
baseline to the last four weeks of the 12-week treatment 
phase 
 
Erenumab: Clinical Impact53,54 
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Phase III ARISE trial: Results 
• Statistically significant reduction in monthly migraine 
days from baseline  
– 2.9-day reduction in the erenumab treatment arm vs. 
1.8-day reduction in the placebo arm 
 
Erenumab: Clinical Impact56 
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Phase II 20120295 study: Design 
• Randomized, placebo-controlled 
• Population: N=667; patients with chronic migraine 
– Average of 18 migraines/month at baseline 
• Intervention: erenumab 140 mg SC or 70 mg SC 
monthly vs. placebo 
• Primary outcome: change in monthly migraine days 
from baseline to the last four weeks of the 12-week 
treatment phase 
 
Erenumab: Clinical Impact53,54 
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Phase II 20120295 study: Results 
• Statistically significant reduction in monthly migraine 
days from baseline 
– 6.6-day reduction in the erenumab treatment arms vs. 
4.2-day reduction in the placebo arm 
 
Erenumab: Clinical Impact56 
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Therapeutic alternatives 
• Acute treatment 
– NSAIDs 
– Combination analgesics (e.g., acetaminophen/aspirin/caffeine) 
– Triptans 
• Prophylactic treatment 
– Amitriptyline 
– Calcium channel blockers 
– Beta blockers 
– Antiepileptics 
– Onabotulinum toxin A 
 
 
Erenumab: Clinical Impact57-60 
NSAID=non-steroidal antiinflammatory drug 
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CGRP Pipeline* 
 
 
Erenumab: Clinical Impact61-64 
Generic/ 
Investigational 
Name 
Stage of 
Development 
Other  
Key Facts 
ALD403 Phase III IV infusion Q3M; also being 
studied as SC, IM injection 
Galcanezumab Phase III SC injection monthly 
TEV-48125 Phase III SC injection monthly 
*Not an all-inclusive list 
IM=intramuscular, Q3M=every three months 
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Erenumab: Clinical Impact53-57,60-65 
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Potential Advantages 
• May be the first targeted 
therapy for prevention of 
migraine 
• Similar safety profile vs. 
placebo in clinical trials 
• CGRP agents may have 
similar efficacy but 
improved safety vs. 
standard oral preventative 
therapies 
Potential Disadvantages 
• Lacking long-term safety 
data to understand impact of 
blocking CGRP receptor 
• SC administration for a 
condition typically treated 
with oral medications 
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Cost 
• Cost data not available 
• Industry news blasts suggest ~$14,000/year 
• Supplemental rebate – select preferred CGRP agent 
• Value-based contracts – reduction in headache 
days/month, patient adherence measures 
 
 
Erenumab: Economic Impact66 
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Volume 
• Prevalence 14.9% of individuals in US 
– Approximately 30% of patients with migraine have used 
preventative therapies 
• Duration: chronic condition; treatment is indefinite 
– Preventative therapies historically associated with poor 
adherence 
• Non-adherence after six months ~65% to 75%  
 
 
 
Erenumab: Economic Impact65,67,68 
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• Medicaid plan 
– $14,000/year for treatment 
– Scenarios 
• 10% uptake:  
$6.3 million/year 
• All candidates for  
preventative therapy 
treated:$62.6 million/year 
• Timeline 
– Approval anticipated ~2018-2019 
 
 
 
 
Erenumab: Budget Impact65,67-69 
100,000  
covered lives 
14,900 
patients with  
migraine 
4,470 
patients  
may require 
preventative  
therapy 
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• Biologics in development may offer first FDA-approved 
targeted treatments for NASH, atopic dermatitis 
• Specialty pipeline agents may offer important 
therapeutic, safety advantages 
• Speciality pipeline agents in existing therapeutic classes 
represent opportunities for supplemental rebate, value-
based contracts 
• Proactive pipeline monitoring and a solid understanding 
of plan membership are key to anticipating budget 
impact of new drugs 
 
 
Conclusions 
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QUESTIONS? 
